Preclinical and clinical studies on naltrexone: What have they taught each other?

Alcoholism: Clinical and Experimental Research

Volumn 27, Issue 3, 2003, Pages 533-539

  Froehlich, Janice ^a   O'Malley, Stephanie ^b   Hyytiä, Petri ^c   Davidson, Dena ^a   Farren, Conor ^d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d ST PATRICK S HOSPITAL   (Ireland)

Author keywords

Alcoholism Treatment; Naloxone; Naltrexone

Indexed keywords

ALCOHOL; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLORNITHYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; FLUOXETINE; NALOXONE; NALTREXONE; NALTRINDOLE; OPIATE ANTAGONIST; PLACEBO; SERTRALINE;

ABSTINENCE; ALCOHOLISM; ANXIETY DISORDER; BEHAVIOR THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG TOLERABILITY; FATIGUE; GENETIC PREDISPOSITION; HEADACHE; HUMAN; INSOMNIA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME; VERTIGO;

ALCOHOLISM; ANIMALS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; HUMANS; NALTREXONE;

ANIMALIA;

EID: 0037345596     PISSN: 01456008     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ALC.0000057943.57330.AB     Document Type: Conference Paper

References (36)

1. Acquas E, Meloni M, Di Chiara G (1993) Blockade of δ-opioid receptors in the nucleus accumbens prevents ethanol-induced stimulation of dopamine release. Eur J Pharmacol 230:239-241.
2. Anton RF, Moak DH, Latham PK (1996) The obsessive compulsive drinking scale. Arch Gen Psychiatry 53:225-231.
3. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK (1999) Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 156:1758-1764.
4. Bohn MJ, Kranzler HR, Beazoglou D, Staehler BA (1994) Naltrexone and brief counseling to reduce heavy drinking. Am J Addict 3:91-99.
5. Brodie MS, Pesold C, Appel SB (1999) Ethanol directly excites dopaminergic ventral tegmental area reward neurons. Alcohol Clin Exp Res 23:1848-1852.
6. Croop RS, Faulkner EB, Labriola, DF (1997) The safety profile of naltrexone in the treatment of alcoholism Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry 54:1130-1135.
7. Farren CK, Rezvani AH, Overstreet D, O'Malley S (2000) Combination pharmacotherapy in alcoholism: a novel treatment approach. CNS Spectrums 5:70-76.
8. Froehlich JC, Zweifel M, Harts J, Lumeng L, Li T-K (1991) Importance of delta opioid receptors in maintaining high alcohol drinking. Psychopharmacology (Berl) 103:467-472.
9. Gatto GJ, McBride WJ, Murphy JM, Lumeng L, Li T-K (1994) Ethanol self-infusion into the ventral tegmental area by alcohol-preferring rats. Alcohol 11:557-564.
10. Heyser CJ, Roberts AJ, Schulteis G, Koob GF (1999) Central administration of an opiate antagonist decreases oral ethanol self-administration in rats. Alcohol Clin Exp Res 23:1468-1476.
11. 1- but not by a δ-opioid receptor antagonist in alcohol-preferring rats. Eur J Pharmacol 304:7-13.
12. Hyytiä P (1993) Involvement of μ-opioid receptors in alcohol drinking by alcohol-preferring AA rats. Pharmacol Biochem Behav 45:697-701.
13. Hyytiä P, Ingman K, Soini SL, Laitinen JT, Korpi ER (1999) Effects of continuous opioid receptor blockade on alcohol intake and up-regulation of opioid receptor subtype signaling in a genetic model of high alcohol drinking. Naunyn Schmiedebergs Arch Pharmacol 360:391-401.
14. Hyytiä P, Kiianmaa K (2001) Suppression of ethanol responding by centrally administered CTOP and naltrindole in AA and Wistar rats. Alcohol Clin Exp Res 25:25-33.
15. Hyytiä P, Sinclair JD (1993) Responding for oral ethanol after naloxone treatment by alcohol-preferring AA rats. Alcohol Clin Exp Res 17:631-636.
16. Johnson B, Ait-Daoud N, Prihoda T (2000) Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypothesis to preliminary clinical evidence. Alcohol Clin Exp Res 24:737-742.
17. 2-opioid receptor antagonist naltriben reduces motivated responding for ethanol. Psychopharmacology 147:81-89.
18. Kranzler HR, Babor TF, Lauerman R (1990) Problems associated with average alcohol consumption and frequency of intoxication in a medical population. Alcohol Clin Exp Res 14:119-126.
19. Kranzler HR, Tennen H, Penta C, Bohn MJ (1997) Targeted naltrexone treatment of early problem drinkers. Addict Behav 22:431-436.
20. Krishnan-Sarin S, Jing S-L, Kurtz DL, Zweifel M, Portoghese PS, Li T-K, Froehlich JC (1995) The delta opioid receptor antagonist naltrindole attenuates both alcohol and saccharin intake in rats selectively bred for alcohol preference. Psychopharmacology 120:177-185.
21. Krishnan-Sarin S, Wand G S, Li XW, Portoghese PS, Froehlich JC (1998) Effect of mu opioid receptor blockade on alcohol intake in rats bred for high alcohol drinking. Pharmacol Biochem Behav 59:627-635.
22. Le A, Sellers E (1996) Interaction between opiate and 5-HT3 receptor antagonists in the regulation of alcohol intake. Alcohol Alcohol 2:545-549.
23. Monterosso JR, Flannery BA, Pettinate HM, Oslin DW, Rukstalis M, O'Brien CP, Volpicelli JR (2001) Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 10:258-268.
24. Nylander I, Hyytiä P, Forsander O, Terenius L (1994) Differences between alcohol-preferring (AA) and alcohol-avoiding (ANA) rats in the prodynorphin and proenkephalin systems. Alcohol Clin Exp Res 18:1272-1279.
25. O'Malley SS (1999) Naltrexone therapy: predictors of adverse events, medication compliance and treatment outcome. Symposium: naltrexone treatment of alcoholism: recent evidence from clinical research. Paper presented at the Research Society on Alcoholism scientific meeting, Santa Barbara, CA, July 1, 1999.
26. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry 49:881-887.
27. Overstreet DH, Kampov-Polevoy AB, Rezvani AH, Braun C, Bartus RT, Crews FT (1999) Suppression of alcohol intake by chronic naloxone treatment in P rats: tolerance development and elevation of opiate receptor binding. Alcohol Clin Exp Res 11:1761-1771.
28. Pert CB, Pasternak G, Snyder SH (1973) Opiate agonists and antagonists discriminated by receptor binding in brain. Science (Washington, DC) 182:1359-1361.
29. Project MATCH RG (1997) Matching alcoholism treatment to client heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol 58:7-29.
30. Rezvani A, Overstreet D, Mason G, Janowsky D, Hamedi M, Clarke EJ, Yang Y (2000) Combination pharmacotherapy: a mixture of small doses of naltrexone, fluoxetine, and a thyrotropin-releasing hormone analogue reduces alcohol intake in three strains of alcohol-preferring rats. Alcohol Alcohol 35:76-83.
31. Salloum IM, Cornelius JR, Thase ME, Daley DC, Kirisci L, Spotts C (1998) Naltrexone utility in depressed alcoholics. Psychopharmacol Bull 34:111-115.
32. Sanders JB, Aasland OG, Babor TF, De La Fuente JR, Grant M (1993) Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction 88:791-804.
33. Sobell LC, Sobell MB, Maisto SA, Cooper AM (1979) Reliability of alcohol abusers' self-reports of drinking behavior. Behav Res Ther 17:157-160.
34. Stromberg MF, Casale M, Volpicelli L, Volpicelli JR, O'Brien, CPA (1998) A comparison of the effects of the opioid antagonists naltrexone, naltrindole, and β-funaltrexamine on ethanol consumption in the rat. Alcohol 15:281-289.
35. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49:876-880.
36. Zukin RS, Sugarman JR, Fitz-Syage ML, Gardner EL, Zukin SR, Gintzler AR (1982) Naltrexone-induced opiate receptor supersensitivity. Brain Res 245:285-292.